Similar to cetuximab, nimotuzumab, an IgG1 isotype antibody, has been shown to be capable of exerting a detrimental effect on EGFR-expressing cancer cells by NK cell-mediated ADCC in patients with SCCHN. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.